XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

Eli Lilly is positioned to become the first healthcare company to reach a $2 trillion market cap by 2031, requiring a 12.7% compound annual growth rate. The company's GLP-1 drug portfolio, led by tirzepatide (Mounjaro/Zepbound), is expected to drive strong revenue growth despite increasing competition. Additional growth catalysts include new product launches like Foundayo, pipeline candidates such as retatrutide, and AI-driven cost efficiencies across the organization.

08/01/2026, 4:17 PM • The Motley Fool

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?

The article compares two healthcare-focused ETFs: Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Healthcare ETF (IYH). FHLC is recommended as the better choice due to its significantly lower expense ratio (0.08% vs 0.38%), broader diversification with 334 holdings versus 100, and consistent outperformance across multiple time periods. Over 10 years, a $10,000 investment in FHLC would have yielded approximately $1,900 more than IYH.

08/01/2026, 1:28 PM • The Motley Fool

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Eli Lilly has significantly outperformed Novo Nordisk in the booming GLP-1 obesity drug market, with Lilly commanding 60% market share compared to Novo's smaller portion of the combined 87% duopoly. While the obesity drug market is projected to grow from $66 billion in 2025 to $120 billion by 2030, Lilly's stock has surged 58% over 52 weeks, whereas Novo has plummeted 62% since July 2024. However, Novo's recent launch of a pill-form obesity drug could shift the competitive landscape.

07/31/2026, 1:30 PM • The Motley Fool

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics, Viking Therapeutics emerges as a potential takeover target due to its promising weight-loss drug pipeline, particularly VK2735 in phase 3 trials. The anti-obesity market is projected to reach $190 billion by 2035, making it attractive for pharmaceutical giants seeking to acquire proven candidates rather than develop from scratch. However, Viking's stock carries significant risk tied to upcoming phase 3 data readouts.

07/30/2026, 6:30 PM • The Motley Fool

Love Dividend Income? Here's 1 ETF Worth Holding.

The Vanguard Dividend Appreciation ETF (VIG) is recommended for investors seeking dividend income with lower risk. The fund tracks U.S. companies that have increased dividends for at least 10 consecutive years, offering low costs (0.04% expense ratio) and stable income rather than maximum yields. While it provides diversification and long-term growth potential, it remains subject to market volatility.

07/30/2026, 11:18 AM • The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.

07/30/2026, 9:09 AM • The Motley Fool

Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock

Eli Lilly is acquiring AtaiBeckley for $2.8 billion to expand beyond weight loss drugs into mental health treatments, including psychedelic-based therapies for treatment-resistant depression. This is the company's 12th acquisition this year and represents a strategic diversification effort, though the mental health market is smaller than the weight loss segment.

07/29/2026, 8:06 AM • The Motley Fool

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Amgen is developing MariTide, a monthly weight loss injection, to compete with Eli Lilly's and Novo Nordisk's weekly GLP-1 drugs. While the monthly dosing offers convenience, MariTide's phase 2 efficacy data don't suggest it will outperform competitors. Eli Lilly and Novo Nordisk are advancing newer therapies including oral and combination drugs, positioning them ahead of Amgen in the competitive weight loss market.

07/29/2026, 7:30 AM • The Motley Fool

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnson maintains steady but modest revenue growth with strong dividend yields and diversified operations, while Eli Lilly demonstrates rapid revenue expansion driven by blockbuster diabetes and obesity drugs Mounjaro and Zepbound. Eli Lilly's revenue has nearly doubled over two years, narrowing the gap with J&J, though investors should monitor patent expiration risks and product concentration for both companies.

07/29/2026, 7:24 AM • The Motley Fool

4 Stocks That Can 4x Your Money in 4 Years

The article discusses four stocks with potential to quadruple investor returns over a four-year period, targeting investors with higher risk tolerance seeking significant upside growth opportunities.

07/28/2026, 11:22 PM • The Motley Fool

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees

Vanguard Health Care ETF (VHT) outperforms VanEck Biotech ETF (BBH) with lower fees (0.09% vs 0.35%), higher dividend yield (1.6% vs 0.5%), and superior 5-year returns ($1,278 vs $1,004 on $1,000 invested). VHT offers broad diversification across 411 healthcare holdings, while BBH provides concentrated biotech exposure with 25 stocks and higher volatility.

07/28/2026, 8:20 AM • The Motley Fool

XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio?

The State Street Health Care Select Sector SPDR ETF (XLV) and Fidelity MSCI Health Care Index ETF (FHLC) both offer low-cost healthcare exposure with identical 0.08% expense ratios. XLV focuses on 60 mega-cap healthcare stocks and has delivered stronger 5-year returns ($1,332 vs $1,276 on $1,000 invested), higher dividend yield (1.60% vs 1.30%), and greater liquidity with $41.7B in AUM. FHLC provides broader diversification with 365 holdings including mid and small-cap stocks. Over 10 years, both underperformed the S&P 500 significantly, with XLV returning 157% (9.9% CAGR) and FHLC returning 159% (10.0% CAGR) versus the S&P 500's 301% (14.9% CAGR).

07/27/2026, 8:35 AM • The Motley Fool

Novo Nordisk A/S - share repurchase programme

Novo Nordisk continues its DKK 15 billion share repurchase programme, having repurchased 25.9 million B shares worth DKK 7.16 billion as of 24 July 2026. The company has also filed a false advertising lawsuit against Eli Lilly over misleading GLP-1 medicine advertising campaigns.

07/27/2026, 6:48 AM • GlobeNewswire

Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?

The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH), which focuses exclusively on 25 pharmaceutical companies with higher returns but higher costs, and State Street Health Care Select Sector SPDR ETF (XLV), which offers broader diversification across 60 healthcare positions with lower fees. While XLV outperforms over 10 years, PPH delivers superior 3-year and 5-year returns. The article recommends PPH for investors seeking recent performance gains, though XLV offers better cost efficiency and diversification.

07/26/2026, 1:01 PM • The Motley Fool